Rare Disease Partnerships Capitalize on recent TK2d data publications and KYGEVVI approval to target rare disease centers, genetics clinics, and patient advocacy groups for expanded access programs, companion diagnostics collaborations, and regional co-promotion opportunities across Europe and beyond.

AI Driven R&D Partnerships UCB's investment in TensorFlow, MATLAB and data standards presents an opening to propose AI and analytics collaborations for translational research, real-world evidence generation, and post-market surveillance services to accelerate drug development and lifecycle management for CNS and immunology programs.

Global Market Expansion With a global footprint spanning nearly 40 countries and established CRM and content platforms (Veeva, Drupal, SharePoint), there are opportunities to partner on market access, local registration, pharmacovigilance, and commercial rollout support in emerging markets and high-potential regions.

Digital Health & Patient Engagement UCB's patient-centric mission aligns with solutions for patient engagement, digital support tools, and outcome tracking; sales opportunities exist in advising on digital therapeutics, patient registries, and healthcare professional engagement platforms that improve adherence and data collection.

Quality & Compliance Solutions ISO 13485 and GDPR readiness indicate a strong need for integrated quality, regulatory, and data governance tools; propose bundled offerings around QMS optimization, regulatory submissions support, and compliant data management across R&D, manufacturing, and patient-facing channels.